__timestamp | TG Therapeutics, Inc. | Xenon Pharmaceuticals Inc. |
---|---|---|
Wednesday, January 1, 2014 | 31354781 | 11768000 |
Thursday, January 1, 2015 | 43445817 | 15152000 |
Friday, January 1, 2016 | 66489820 | 19828000 |
Sunday, January 1, 2017 | 96886134 | 25573000 |
Monday, January 1, 2018 | 153793000 | 23634000 |
Tuesday, January 1, 2019 | 148369000 | 38845000 |
Wednesday, January 1, 2020 | 151934000 | 50523000 |
Friday, January 1, 2021 | 198532000 | 75463000 |
Saturday, January 1, 2022 | 112128000 | 105767000 |
Sunday, January 1, 2023 | 76192000 | 167512000 |
Cracking the code
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, TG Therapeutics, Inc. and Xenon Pharmaceuticals Inc. have demonstrated contrasting strategies in their R&D allocations. From 2014 to 2023, TG Therapeutics increased its R&D expenses by approximately 143%, peaking in 2021. However, a notable decline of around 62% was observed by 2023. In contrast, Xenon Pharmaceuticals exhibited a steady upward trajectory, with a remarkable 1,324% increase in R&D spending over the same period, culminating in 2023. This divergence highlights TG Therapeutics' fluctuating investment approach, while Xenon Pharmaceuticals consistently bolstered its R&D efforts, potentially positioning itself for future breakthroughs. As the biotech sector evolves, these spending patterns may offer insights into each company's strategic priorities and potential market impact.
Comparing Innovation Spending: Eli Lilly and Company and TG Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Novo Nordisk A/S and TG Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Takeda Pharmaceutical Company Limited and TG Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.
R&D Spending Showdown: Genmab A/S vs TG Therapeutics, Inc.
Bio-Techne Corporation vs Xenon Pharmaceuticals Inc.: Strategic Focus on R&D Spending
BioMarin Pharmaceutical Inc. vs TG Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Axsome Therapeutics, Inc. and TG Therapeutics, Inc.
TG Therapeutics, Inc. vs Catalyst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: PTC Therapeutics, Inc. vs Xenon Pharmaceuticals Inc.
Who Prioritizes Innovation? R&D Spending Compared for Perrigo Company plc and Xenon Pharmaceuticals Inc.
Research and Development Expenses Breakdown: Xenon Pharmaceuticals Inc. vs Travere Therapeutics, Inc.